{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:28:16Z","timestamp":1794360496610,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jaci.2016.08.056","type":"journal-article","created":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T02:02:20Z","timestamp":1483236140000},"page":"109-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":372,"title":["IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-9402","authenticated-orcid":false,"given":"Andrew","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Wolterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew H.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiQiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Reingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michelle","family":"Kahlenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2016.08.056_bib1","article-title":"Psoriasis","volume":"chapter 18","author":"Gudjonsson","year":"2012"},{"key":"10.1016\/j.jaci.2016.08.056_bib2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.08.056_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2016.08.056_bib4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/jid.2012.490","article-title":"Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes","volume":"133","author":"Setta-Kaffetzi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib5","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","article-title":"Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation","volume":"67","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib7","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2353\/ajpath.2010.090746","article-title":"A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue","volume":"177","author":"Hodgin","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2016.08.056_bib8","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1093\/nar\/gni179","article-title":"Evolving gene\/transcript definitions significantly alter the interpretation of GeneChip data","volume":"33","author":"Dai","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaci.2016.08.056_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","author":"Irizarry","year":"2003","journal-title":"Biostatistics"},{"key":"10.1016\/j.jaci.2016.08.056_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"10.1016\/j.jaci.2016.08.056_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2144\/03342mt01","article-title":"TM4: a free, open-source system for microarray data management and analysis","volume":"34","author":"Saeed","year":"2003","journal-title":"Biotechniques"},{"key":"10.1016\/j.jaci.2016.08.056_bib12","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting\u00a0genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2016.08.056_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1755-8794-7-27","article-title":"Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era","volume":"7","author":"Swindell","year":"2014","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jaci.2016.08.056_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/1471-2164-14-527","article-title":"Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients","volume":"14","author":"Swindell","year":"2013","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jaci.2016.08.056_bib15","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","article-title":"ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks","volume":"25","author":"Bindea","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jaci.2016.08.056_bib16","first-page":"unit 7.23","article-title":"Isolation and functional analysis of neutrophils","volume":"chapter 7","author":"Clark","year":"2001","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.jaci.2016.08.056_bib17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2016.08.056_bib18","doi-asserted-by":"crossref","first-page":"24880","DOI":"10.1038\/srep24880","article-title":"Neutrophil elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 receptor antagonist","volume":"6","author":"Macleod","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2016.08.056_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/gb-2006-7-5-216","article-title":"An overview of the serpin superfamily","volume":"7","author":"Law","year":"2006","journal-title":"Genome Biol"},{"key":"10.1016\/j.jaci.2016.08.056_bib20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.det.2014.09.009","article-title":"Ten years on: the impact of biologics on the practice of dermatology","volume":"33","author":"Leonardi","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2016.08.056_bib22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2016.08.056_bib23","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1038\/jid.2013.214","article-title":"Mutations in IL36RN in patients with generalized pustular psoriasis","volume":"133","author":"Korber","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","article-title":"AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking","volume":"94","author":"Setta-Kaffetzi","year":"2014","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2016.08.056_bib25","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","article-title":"PSORS2 is due to mutations in CARD14","volume":"90","author":"Jordan","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2016.08.056_bib26","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression","volume":"186","author":"Johnston","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.08.056_bib27","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1084\/jem.20070157","article-title":"Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation","volume":"204","author":"Blumberg","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2016.08.056_bib28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4049\/jimmunol.167.3.1440","article-title":"Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2","volume":"167","author":"Debets","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.08.056_bib29","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in\u00a0vitro and in\u00a0vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib30","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.08.056_bib31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/eji.201142035","article-title":"Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9","volume":"42","author":"Mutamba","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2016.08.056_bib32","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2016.08.056_bib33","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1073\/pnas.1115884109","article-title":"IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G","volume":"109","author":"Lefrancais","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2016.08.056_bib34","doi-asserted-by":"crossref","first-page":"15502","DOI":"10.1073\/pnas.1410700111","article-title":"Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells","volume":"111","author":"Lefrancais","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2016.08.056_bib35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2014.02.002","article-title":"Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations","volume":"134","author":"Snelgrove","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.08.056_bib36","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2016.08.056_bib37","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1542\/peds.2012-3935","article-title":"First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra","volume":"132","author":"Rossi-Semerano","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2016.08.056_bib38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjd.12548","article-title":"Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations","volume":"170","author":"Huffmeier","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-153-1-201007060-00030","article-title":"Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations","volume":"153","author":"Viguier","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2016.08.056_bib40","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/bjd.12805","article-title":"Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?","volume":"170","author":"Tauber","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib41","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1067\/mjd.2002.128382","article-title":"Infliximab for the treatment of severe pustular psoriasis","volume":"47","author":"Elewski","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-4362.2002.01543.x","article-title":"Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type","volume":"41","author":"Newland","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjd.12937","article-title":"Early tissue responses in psoriasis to the antitumour necrosis factor-alpha biologic etanercept suggest reduced interleukin-17 receptor expression and signalling","volume":"171","author":"Johnston","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib45","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamadermatol.2015.4686","article-title":"Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab","volume":"152","author":"Bohner","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib46","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/1346-8138.13306","article-title":"Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study","volume":"43","author":"Imafuku","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib47","article-title":"Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study","author":"Yamasaki","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.08.056_bib48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/13543776.2014.881473","article-title":"Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569","volume":"24","author":"Wolf","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jaci.2016.08.056_bib49","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4049\/jimmunol.1400538","article-title":"Molecular determinants of agonist and antagonist signaling through the IL-36 receptor","volume":"193","author":"Gunther","year":"2014","journal-title":"J Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674916324897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674916324897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:04:29Z","timestamp":1758791069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674916324897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0091674916324897"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2016.08.056","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2016.08.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}